Celsus Therapeutics Provides Update on MRX-6 From FDA Pre-IND Meeting
March 11, 2014 16:05 ET
|
Celsus Therapeutics
Celsus completes Type B pre-IND meeting with FDA for MRX-6 cream in atopic dermatitis
MRX-6 to advance into Phase II trials in US upon filing of IND expected in 4Q14
NEW YORK and LONDON,...
Celsus Therapeutics to Present at the 2014 BIO CEO & Investor Conference
February 06, 2014 07:30 ET
|
Celsus Therapeutics
NEW YORK and LONDON, Feb. 6, 2014 (GLOBE NEWSWIRE) -- Celsus Therapeutics Plc (Nasdaq:CLTX), an emerging growth, development-stage biotech company, announced today that Dr. Gur Roshwalb, Chief...
Celsus Therapeutics Announces the Closing of $9.2 Million Public Offering and Full Exercise of Underwriter's Option to Purchase Additional ADSs
February 05, 2014 16:05 ET
|
Celsus Therapeutics
NEW YORK and LONDON, Feb. 5, 2014 (GLOBE NEWSWIRE) -- Celsus Therapeutics Plc (Nasdaq:CLTX), an emerging growth, development-stage biotech company, announced today the closing of its previously...
Celsus Therapeutics Announces Pricing of Public Offering and Listing on NASDAQ
January 30, 2014 17:32 ET
|
Celsus Therapeutics
NEW YORK and LONDON, Jan. 30, 2014 (GLOBE NEWSWIRE) -- Celsus Therapeutics Plc (Nasdaq:CLTX) (formerly OTCQB:CLSXD), an emerging growth, development-stage biotech company, announced today the pricing...
Celsus Therapeutics Announces Appointment of Pablo Jimenez, M.D., to Chief Medical Officer
October 24, 2013 08:15 ET
|
Celsus Therapeutics
NEW YORK and LONDON, Oct. 24, 2013 (GLOBE NEWSWIRE) -- Celsus Therapeutics (OTCQB:CLSXY), an emerging growth, development-stage biopharmaceutical company, announces the appointment of Pablo Jimenez,...
Celsus Therapeutics' MRX-6 Selected as One of the "Top Autoimmune/Anti-Inflammatory Disease Projects to Watch" by Elsevier Business Intelligence
October 21, 2013 08:15 ET
|
Celsus Therapeutics
- MRX-6 is a Topical, Non-Steroidal Anti-Inflammatory Cream in Phase II Trials for Eczema
- Celsus to present MRX-6 at Windover's Therapeutic Area Partnerships meeting
NEW YORK and LONDON, Oct....
Celsus Therapeutics Names Allan Shaw to Board of Directors
October 02, 2013 08:15 ET
|
Celsus Therapeutics
NEW YORK and LONDON, Oct. 2, 2013 (GLOBE NEWSWIRE) -- Celsus Therapeutics (OTCQB:CLSXY), an emerging growth, development-stage biopharmaceutical company, announced today the addition of...
Celsus Therapeutics Closes $12.5 Million Private Placement
September 30, 2013 16:10 ET
|
Celsus Therapeutics
NEW YORK and LONDON, Sept. 30, 2013 (GLOBE NEWSWIRE) -- Celsus Therapeutics (OTCQB:CLSXY), an emerging growth, development-stage biopharmaceutical company, announced today that it has closed a...
Celsus Therapeutics Announces $12.5 Million Private Placement
September 19, 2013 08:21 ET
|
Celsus Therapeutics
NEW YORK and LONDON, Sept. 19, 2013 (GLOBE NEWSWIRE) -- Celsus Therapeutics (OTCQB:CLSXY), an emerging growth, development-stage biotechnology company, announced today that it has entered into a...
Celsus Therapeutics Announces ADR Ticker Symbol Change to CLSXY
September 17, 2013 07:00 ET
|
Celsus Therapeutics
NEW YORK and LONDON, Sept. 17, 2013 (GLOBE NEWSWIRE) -- Celsus Therapeutics (OTCQB:CLSXY), an emerging growth, development-stage biotechnology company, announced that effective September 16, 2013, the...